RESUMO
BACKGROUND: WC and NS contributed equally. Non-tuberculous mycobacteria (NTM) frequently colonise patients with end stage cystic fibrosis (CF), but its impact on the course of the disease following lung transplantation is unknown. METHODS: Lung transplant recipients with CF who underwent lung transplantation at our institution between January 1990 and May 2003 (n=146) and CF patients awaiting lung transplantation in May 2003 (n=31) were studied retrospectively. RESULTS: The prevalence rate of NTM isolated from respiratory cultures in patients with end stage CF referred for lung transplantation was 19.7%, compared with a prevalence rate of 13.7% for NTM isolates in CF lung transplant recipients. The overall prevalence of invasive NTM disease after lung transplantation was low (3.4%) and was predicted most strongly by pre-transplant NTM isolation (p=0.001, Fisher's exact test, odds ratio (OR) 6.13, 95% CI 3.2 to 11.4). This association was restricted to Mycobacterium abscessus (p = 0.005, Fisher's exact test, OR 7.45, 95% CI 2.9 to 16.9). While NTM disease caused significant morbidity in a small number of patients after transplantation, it was successfully treated and did not influence the post-transplant course of the disease. CONCLUSION: The isolation of NTM before transplantation in CF patients should not be an exclusion criterion for lung transplantation, but it may alert the clinician to patients at risk of recurrence following transplantation.
Assuntos
Fibrose Cística/microbiologia , Transplante de Pulmão , Infecções por Mycobacterium não Tuberculosas/microbiologia , Tuberculose Pulmonar/microbiologia , Adolescente , Adulto , Fibrose Cística/fisiopatologia , Fibrose Cística/cirurgia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecções por Mycobacterium não Tuberculosas/fisiopatologia , Micobactérias não Tuberculosas/isolamento & purificação , Testes de Função Respiratória , Estudos Retrospectivos , Tuberculose Pulmonar/fisiopatologiaRESUMO
Pseudomonas aeruginosa commonly colonizes the airways of patients with cystic fibrosis (CF). However, the occurrence of bacteremia with metastatic infection to the eye causing endogenous endophthalmitis is very rare. In the setting of lung transplantation, the significance of P. aeruginosa bacteremia in patients with CF whose airways are colonized before transplantation is unknown. We report a case of bilateral P. aeruginosa endogenous endophthalmitis in a patient with CF after lung transplant without documented bacteremia. The patient presented with acute eye symptoms in the presence of a left atrial thrombus and the disease followed a rapidly progressive course requiring aggressive medical-surgical treatment. Typically P. aeruginosa endophthalmitis has been associated with a poor visual prognosis. However, with combined medical-surgical management this patient retained useful vision in one eye without having retinal detachment or requiring enucleation. Endogenous endophthalmitis should be considered in the differential diagnosis of ocular complaints in patients with CF after lung transplant.
Assuntos
Fibrose Cística/cirurgia , Endoftalmite/diagnóstico , Transplante de Pulmão , Infecções por Pseudomonas/diagnóstico , Adulto , Fibrose Cística/complicações , Fibrose Cística/diagnóstico por imagem , DNA Bacteriano/análise , Diagnóstico Diferencial , Endoftalmite/microbiologia , Feminino , Humanos , Pulmão/química , Pulmão/diagnóstico por imagem , Pulmão/microbiologia , Infecções por Pseudomonas/etiologia , Pseudomonas aeruginosa/isolamento & purificação , Retina/patologia , Tomografia Computadorizada por Raios X , Ultrassonografia , Corpo Vítreo/química , Corpo Vítreo/diagnóstico por imagem , Corpo Vítreo/microbiologiaRESUMO
BACKGROUND: The state of tolerance allows long term graft survival without immunosuppressants. Lung transplantation tolerance has not been consistently achieved in either small or large animal models. METHODS: The mechanisms and effectiveness of a tolerance induction protocol consisting of donor specific transfusion (DST; day 0) and a short course of co-stimulatory blockade (anti-CD154 antibody; days -7, -4, 0 and +4) were studied in the mouse heterotopic tracheal transplant model of chronic lung rejection. C57BL/6 mice received BALB/c tracheal grafts (day 0) and were treated with DST alone, anti-CD154 alone, the combination (DST/anti-CD154), or no treatment. No non-specific immunosuppressants were used. RESULTS: DST/anti-CD154 in combination, but neither treatment alone, markedly prolonged the lumen patency and survival (>100 days) of fully histo-incompatible allografts (p<0.05 versus control allografts at every time point studied up to 16 weeks) without immunosuppression. This protocol was donor antigen specific as third party grafts (C3H) were promptly rejected. In addition, DST/anti-CD154 did not result in mixed chimerism but induced transplantation tolerance via a peripheral mechanism(s), which included significantly reduced cytotoxic T cell activity (p<0.001) and a significantly increased percentage of CD4+CD25+ cells (p = 0.03). CONCLUSIONS: The DST/anti-CD154 protocol successfully induced and maintained long term, donor specific tolerance in the mouse heterotopic airway graft model of chronic lung rejection. This finding may lead us closer to successful tolerance induction in lung transplantation.
Assuntos
Ligante de CD40/uso terapêutico , Rejeição de Enxerto/prevenção & controle , Transplante de Pulmão , Traqueia/transplante , Animais , Feminino , Fluoresceínas , Corantes Fluorescentes , Imuno-Histoquímica , Camundongos , Camundongos Endogâmicos BALB C , Succinimidas , Linfócitos T Citotóxicos/imunologia , Transplante HomólogoRESUMO
BACKGROUND: Unlike Goodpasture's syndrome with diffuse alveolar hemorrhage (DAH), there are few studies examining therapy for patients with DAH associated with antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis (SVV). METHODS: We performed a retrospective review of all such patients presenting to our institution between 1995 and 2001. All patients were treated with apheresis and induction immunosuppressive therapy; namely, intravenous methylprednisolone and/or intravenous cyclophosphamide. RESULTS: DAH resolved with apheresis in 20 of 20 patients (100%) with 6.4 (average) treatments. There were no complications of therapy. Half the patients (7 of 14) who also presented with azotemia were discharged with improved renal function. CONCLUSION: Patients with ANCA-related SVV and DAH benefit from prompt initiation of apheresis coupled with aggressive immunosuppressive therapy. Such therapy can be lifesaving with respect to the pulmonary component of this syndrome.
Assuntos
Anticorpos Anticitoplasma de Neutrófilos/imunologia , Doenças Autoimunes/terapia , Hemorragia/terapia , Pneumopatias/terapia , Plasmaferese , Vasculite/complicações , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças Autoimunes/etiologia , Síndrome de Churg-Strauss/complicações , Síndrome de Churg-Strauss/tratamento farmacológico , Terapia Combinada , Ciclofosfamida/uso terapêutico , Feminino , Granulomatose com Poliangiite/complicações , Granulomatose com Poliangiite/tratamento farmacológico , Hemorragia/tratamento farmacológico , Hemorragia/etiologia , Humanos , Imunossupressores/uso terapêutico , Pneumopatias/tratamento farmacológico , Pneumopatias/etiologia , Masculino , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Alvéolos Pulmonares , Estudos Retrospectivos , Resultado do Tratamento , Vasculite/tratamento farmacológicoRESUMO
Cystic fibrosis (CF) patients often have low bone mineral density (BMD) and may suffer from fractures and kyphosis. The pathogenesis of low BMD in CF is multifactorial. To study bone metabolism, we collected fasting serum and urine from 50 clinically stable CF adults (mean age 28 years) and 53 matched controls to measure markers of bone formation and bone resorption. The CF subjects had moderate lung disease (FEV1: 46.1 +/- 18.6% predicted) and malnutrition (BMI: 20.0 +/- 3.3 kg/m2). Only 3 subjects had normal BMD. CF subjects had higher urinary N-telopeptides of type I collagen (81.0 +/- 60.0 vs 49.0 +/- 24.2 nm BCE/mmol creatinine, p = 0.0006) and free deoxypyridinoline (7.3 +/- 5.0 vs 5.3 +/- 1.9 nM/mM, p = 0.004) levels than controls. Serum osteocalcin levels were similar in the two groups, a result confirmed by two immunoassays that recognize different epitopes on osteocalcin. Serum bone-specific alkaline phosphatase levels were elevated in CF patients (32.0 +/- 11.3 vs 21.8 +/- 7.0 U/l, p < 0.0001), but were much more closely associated with serum total alkaline phosphatase levels (r = 0.51, p = 0.001) than with age or gender. Parathyroid hormone levels were elevated (p = 0.007) and 25-hydroxyvitamin D levels were depressed (p = 0.0002) in the CF patients in comparison with controls. These results indicate that adults with CF have increased bone resorption with little change in bone formation. Medications that decrease bone resorption or improve calcium homeostasis may be effective therapies for CF bone disease.
Assuntos
Fibrose Cística/complicações , Osteoporose/etiologia , Adolescente , Adulto , Biomarcadores/análise , Densidade Óssea , Remodelação Óssea , Osso e Ossos/metabolismo , Proteína C-Reativa/metabolismo , Estudos de Casos e Controles , Fibrose Cística/metabolismo , Fibrose Cística/fisiopatologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Osteoporose/metabolismo , Osteoporose/fisiopatologia , Hormônio Paratireóideo/sangue , Vitamina D/sangueRESUMO
Although various forms of Aspergillus disease are not uncommonly encountered in lung transplant recipients, Aspergillus endocarditis has never been reported. A case of Aspergillus endocarditis in a lung transplant recipient is presented here and is among 10 total cases reported in the solid organ transplant literature. This case is used to compare and contrast the clinical features of all of the reported cases with special emphasis on common characteristics that may aid in future case diagnoses and treatment. Pre-mortem diagnosis is difficult. Rapid diagnosis and combined medical and surgical therapy are essential for an optimal outcome.